VivoSeq
Cardiovascular

Rheumatic Heart Disease

8

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Rheumatic Heart Disease is an early-stage landscape with 8 programs across 4 companies. The most active players are Roche, Novartis, Bayer. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Bayer logo

Bayer

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

8 of 9 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

7

clinical trials

Active, not recruiting2 · 29%
Not yet recruiting2 · 29%
Unknown status1 · 14%
Completed1 · 14%
Recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop
Recruiting·CChildren's Hospital Medical Center, Cincinnati·Phase 3·NCT07146048·922 enrolled
Role of Statins In Slowing Rheumatic Heart Disease (RHD) Progression
Active, not recruiting·UUniversity of Washington·N/A·NCT04575857·100 enrolled
Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A Non-inferiority Randomized Trial
Active, not recruiting·CChildren's Hospital Medical Center, Cincinnati·Phase 2·NCT05693545·1,004 enrolled
Adapting Enhanced Supports to Improve Patient Adherence to Secondary Antibiotic Prophylaxis for Rheumatic Heart Disease
Not yet recruiting·CChildren's Hospital Medical Center, Cincinnati·N/A·NCT07666048·308 enrolled
Developing and Testing a Registry-Enabled Strategy (ACT+) to Reduce Loss to Follow-Up Between Screening and Confirmation of Rheumatic Heart Disease in Uganda
Not yet recruiting·CChildren's Hospital Medical Center, Cincinnati·Preclinical·NCT07606131·16 enrolled
N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement
Completed·—·Phase 2·NCT01704482·60 enrolled
Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass
Unknown status·NNanjing Medical University·N/A·NCT05487469·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)